Table 4.
Concomitant medication use and prescribing patterns for Pneumocystis jirovecii pneumonia (PCP) prophylaxis.
| Immunosuppressive Medication | Prescribed PJP prophylaxis*n (%) |
|---|---|
| Renal transplant conditioning regimens** | 32/56 (57) |
| Calcineurin and mTOR inhibitors | 52/119 (44) |
| Cyclophosphamide | 43/168 (26) |
| Mycophenolate mofetil or mycophenolic acid | 78/326 (24) |
| Rituximab | 20/97 (21) |
| Belimumab | 7/72 (10) |
| Azathioprine | 16/305 (5) |
| Other biologic DMARDs*** | 3/74 (4) |
| Methotrexate | 7/219 (3) |
| Leflunomide | 0/37 (0) |
| Glucocorticoids (≥ prednisone 20 mg/day) | 125/170 (74) |
| Current Regimen, n (%) **** | |
| 0 DMARDS with GC | 19/170 (11) |
| 1 DMARD with GC | 52/170 (31) |
| 2+ DMARDs with GCs | 54/170 (32) |
| 1 DMARD without GC | 9/170 (5) |
| 2+ DMARDS without GC | 28/170 (16) |
| None or Unknown | 8/170 (5) |
| Prescribing Provider | |
| Rheumatology | 64/170 (38) |
| Nephrology | 71/170 (42) |
| Pulmonology/Critical Care | 13/170 (8) |
| Hematology/Oncology | 9/170 (5) |
| Infectious Disease | 2/170 (1) |
| Neurology | 1/170 (1) |
| Unclear | 10/170 (6) |
| Patient Location | |
| Inpatient | 110/170 (65) |
| Outpatient | 50/170 (29) |
| Unknown | 10/170 (6) |
*
For each instance a patient was started on PJP prophylaxis, we conducted chart review to determine the medications they were on at the time PJP prophylaxis was started.
**
Medications included thymoglobulin, alemtuzumab, or basiliximab.
***
Medications included TNF inhibitors, anakinra, and abatacept.
****
Immunosuppressive regimen at time of PJP prophylaxis start. DMARD (Disease modifying antirheumatic drugs), GC (Glucocorticoids) = Greater than or equal to the equivalent of prednisone 20 mg daily.